Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06772597
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
- Conditions
- Hypothalamic ObesityMultiple Pituitary Hormone Deficiency Genetic FormSepto-Optic DysplasiaOptic Nerve HypoplasiaChildhood-onset Combined Pituitary Hormone DeficiencyPituitary Stalk Interruption Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06760546
Open-Label Extension Study of Setmelanotide
- Conditions
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06596135
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸UC San Diego- Rady Children's Hospital, San Diego, California, United States
🇺🇸University of Florida at Gainesville, Gainesville, Florida, United States
A Study of RM-718 in Healthy Subjects and in Patients With HO
- Conditions
- Hypothalamic Obesity
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06239116
- Locations
- 🇺🇸
UAB Pediatric Endocrinology, Birmingham, Alabama, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06046443
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
- Conditions
- Hypothalamic Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05774756
- Locations
- 🇬🇧
Birmingham Women and Children's Hospital NHS Trust, Birmingham, United Kingdom
🇺🇸Ohio State Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
- Conditions
- Bardet-Biedl SyndromePOMC Deficiency
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT05194124
- Locations
- 🇵🇷
UPR Medical Sciences Campus, Rio Piedras, Puerto Rico
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇩🇪Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
- Conditions
- Bardet-Biedl Syndrome (BBS)Obesity
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Registration Number
- NCT05183802
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
- Conditions
- Genetic ObesityObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05093634
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸HonorHealth Bariatric Center, Scottsdale, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT05046132
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit (Los Angeles), Glendale, California, United States